Topics

A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia

2019-05-06 17:20:30 | BioPortfolio

Summary

The aim of this 12-week randomized multicenter double-blind double-dummy parallel group placebo and active comparator-controlled dose finding study is to assess the efficacy and safety of four different doses of LC350189 in subjects with hyperuricemia and a diagnosis of gout.

Study Design

Conditions

Gout

Intervention

Xanthine Oxidase Inhibitor, Xanthine Oxidase Inhibitor, Placebo

Status

Not yet recruiting

Source

LG Chem

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-05-06T17:20:30-0400

Clinical Trials [3088 Associated Clinical Trials listed on BioPortfolio]

Post-Authorisation Safety Study of Lesinurad

Non-interventional population-based prospective cohort study in multiple databases comparing patients with gout who initiate lesinurad in combination with an existing xanthine oxidase inhi...

The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.

This is a Phase 1, open-label, fixed-sequence, 3-period, 2-way drug interaction study designed to assess the PK, PD, safety, and tolerability of LC350189 and colchicine when administered a...

The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults

This is a Phase 1, open-label, fixed-sequence, 3-period, 2-way drug interaction study designed to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of LC350189 and Na...

Role of Allopurinol on Oxidative Stress and Mitochondrial Alterations in Skeletal Muscle of Diabetic Patients

Our recent data in mice have demonstrated a key role of xanthine oxidase in hyperglycemia-induced by Reactive oxygen species production, and a preventive role of allopurinol (inhibitor of ...

Uric Acid and Hypertension in African Americans

This study will test the hypothesis that the administration of a xanthine oxidase inhibitor (allopurinol) will prevent thiazide-induced hyperuricemia, which will result in better blood pre...

PubMed Articles [5464 Associated PubMed Articles listed on BioPortfolio]

Targeting the subpocket in xanthine oxidase: Design, synthesis, and biological evaluation of 2-4-alkoxy-3-(1H-tetrazol-1-yl) phenyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives.

Xanthine oxidase is an important target for the treatment of hyperuricemia, gout and other related diseases. Analysis of the high-resolution structure of xanthine oxidase with febuxostat identified th...

Xanthine oxidase inhibitory activity of isoflavonoids from Apios americana.

Xanthine oxidase (XO) is a form of xanthine oxidoreductase, a type of enzyme that plays a key role in the induction of hyperuricemia and raising superoxide radical level in blood. The present study wa...

Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users.

The aim of this study is to determine major adverse cardiovascular events (MACE) and all-cause mortality comparing between xanthine oxidase inhibitors (XOIs) and non-XOI users, and between allopurinol...

Study on the spectrum-effect relationship of the xanthine oxidase inhibitory activity of Ligustrum lucidum.

To evaluate the xanthine oxidase inhibitory activity of the chemical constituents of Ligustrum lucidum in vitro, the spectrum-effect relationship was investigated. The HPLC fingerprint was established...

Synthesis, biological evaluation and molecular docking studies of bis-chalcone derivatives as xanthine oxidase inhibitors and anticancer agents.

In this study, a series of B-ring fluoro substituted bis-chalcone derivatives were synthesized by Claisen-Schmidt condensation reactions and evaluated for their ability to inhibit xanthine oxidase (XO...

Medical and Biotech [MESH] Definitions

A thiazole derivative and inhibitor of XANTHINE OXIDASE that is used for the treatment of HYPERURICEMIA in patients with chronic GOUT.

A xanthine oxidase inhibitor.

An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.

A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.

A metallic element with the atomic symbol Mo, atomic number 42, and atomic weight 95.94. It is an essential trace element, being a component of the enzymes xanthine oxidase, aldehyde oxidase, and nitrate reductase. (From Dorland, 27th ed)

More From BioPortfolio on "A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia"

Quick Search

Relevant Topics

Gout
According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...


Searches Linking to this Trial